Chengdu Easton Biopharmaceuticals Co., Ltd.SSE: 688513

(688513)"Chengdu Easton Biopharmaceuticals Co., Ltd."Report for Q3 2026

· Issued by Chengdu Easton Biopharmaceuticals Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Stock code 688513 · · 12 pages · Chinese

Summary by 6ix AI

The report indicates a decline in both revenue and net profit compared to the same period last year, with significant reductions in key financial metrics. The company has emphasized its commitment to the accuracy and completeness of the report, asserting that it has not been audited. Additionally, the report highlights an increase in research and development expenditures as part of its strategic focus on innovation.

Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

Chengdu Easton Biopharmaceuticals Co., Ltd. on 6ix

Earlier from Chengdu Easton Biopharmaceuticals

Later from Chengdu Easton Biopharmaceuticals

All Chengdu Easton Biopharmaceuticals news releases